Korro Bio, Inc. — Form 8-K summary
Reporting date: October 5, 2026. This current report describes an event announced on that date; it does not report a financial period.
Business context and material event
Korro Bio announced that it dosed the first cohort of participants in ANCHOR, its Phase 1/2 clinical trial of KRRO-121. The company describes KRRO-121 as a GalNAc-conjugated RNA-editing oligonucleotide being developed for potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy.
Financial information
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It contains no comparable-period financial results.
Outlook, risks and contingencies
The filing reports a clinical-trial milestone but provides no trial results, guidance, timeline, or detailed risk or contingency information. The stated treatment use is potential, not an established outcome.
Investor facts to verify
- Review Exhibit 99.1, the October 5 press release, for additional trial details; its full text is not included in the provided filing text.
- Verify the trial design, planned endpoints, participant numbers, and expected timing of updates from company disclosures.
- Monitor subsequent disclosures for safety, efficacy, enrollment, and any changes to the program.